Medtech Archives - Page 7 of 8

Atlas Venture, F-Prime Capital Partners and SV Health Investors to Host Symposium Featuring Therapeutics Startup Ideas From World’s Top Academic Research Institutions

April 12, 2018

Science 2 Startup Symposium Will Take Place in Cambridge on April 24, 2018, at the Broad Institute of MIT and Harvard

CAMBRIDGE, Mass., April 12, 2018 (GLOBE NEWSWIRE) — Boston-area venture capital firms Atlas Venture, F-Prime Capital Partners and SV Health Investors have partnered to create Science 2 Startup, an invitation-only symposium aimed at strengthening connections between biotech investors and therapeutics researchers at the world’s top academic research institutions. Science 2 Startup will take place on April 24, 2018, in Cambridge at the Broad Institute of MIT and Harvard.

The day-long event will feature presentations of promising therapeutics in development, ones that could be part of a new generation of startups, by the participating universities’ principal investigators. There will also be a panel discussion entitled “Building Successful Biotechnology Companies” and a keynote, “The Biotech Ecosystem: Success and Challenges”, by Dan Lynch, Chairman of the Board of six biotech companies, including bluebird bio and Blueprint Medicines. Attendees at Science 2 Startup will include investors from life sciences-focused venture capital firms, top biotech entrepreneurs and senior people from the pharmaceutical industry. Goodwin, Deloitte, Alexandria Venture Investments and Silicon Valley Bank are the event’s sponsors.

Zenflow Raises $31.4M in Series A Funding

February 7, 2018

Zenflow, Inc., a San Francisco, CA-based medical device company, closed a $31.4m Series A equity financing round.

The round was led by Invus Opportunities, F-Prime Capital Partners, and Medical Technology Venture Partners.

The company, which has also received grant funding from the National Institutes of Health (NIH) and National Science Foundation (NSF).

Founded by Nick Damiano and Shreya Mehta out of the Stanford Biodesign Innovation Fellowship in 2014, Zenflow develops minimally invasive devices to treat obstructive urinary symptoms related to benign prostatic hyperplasia (BPH or enlarged prostate). Its first product is the Spring System, a technology device that delivers a low-profile superelastic implant into the prostatic urethra. This system is intended to permanently relieve BPH symptoms in a single procedure with fast recovery and minimal side effects.

Amphora Medical Closes $35.5 Million Series B Financing

July 20, 2017

MINNEAPOLIS — Amphora Medical, Inc., a developer of medical devices to treat overactive bladder (OAB), today announced the closing of a $35.5 million Series B financing. The financing was led by Longitude Capital and Boston Scientific Corporation (NYSE:BSX), and included participation by HBM Healthcare Investments, as well as existing venture investors F-Prime Capital Partners and Baird Capital. Amphora will use the proceeds from this financing to fund the U.S. pivotal study for its Selective Bladder Denervation System in women with OAB.

OAB is characterized by the frequent, sudden and desperate need to urinate, with or without urgency-associated urinary incontinence, which interferes with normal daily activities. Amphora’s propriety Selective Bladder Denervation System is a minimally-invasive, cystoscopic device which uses targeted ablation (fulguration) to dampen the signals of the nerves responsible for the symptoms of OAB at their source in the bladder, while preserving the nerves responsible for natural bladder function.

F-Prime Capital ranked #2 in top 100 biotech VCs

June 27, 2016

2015 proved to be the biggest year on record for venture investing in U.S. biotechs. A total of $7.7 billion flowed into a range of startups, some clustered in Boston/Cambridge and San Francisco, but with quite a large amount finding its way to drug developers off the beaten biotech path.

This year the money has continued to flow at the same torrid pace, even though the IPO window for drug developers has dropped down to an uncomfortable squeeze space for the hottest, or most desperate, companies to aim at.

But how do the VCs rank in terms of deals and dollars? I asked Thomson Reuters, which does the numbers for the MoneyTree Report from PricewaterhouseCoopers LLP and the National Venture Capital Association, and they came back with the list below.

Trivitron patents NeoMass AAAC kit for newborn screening to detect 50 inborn disorders

January 12, 2016

Trivitron Healthcare has launched NeoMass AAAC Kit (CE Approved) for expanded panel of newborn screening in India. This is the first kit in the global market that can detect up to 50 disorders that a newborn baby might be born with or without any immediate symptoms or visible manifestations, making it the broadest available panel of biomarkers. The launch of NeoMass AAAC Kit makes Trivitron a complete solution provider for NBS with modular systems, automated systems and kits for core panel screening and Tandem MS/ MS and NeoMass AAAC kit for expanded panel screening. Dr Ralph Fingerhut, Director Swiss Newborn Screening Laboratory University Children’s Hospital, Zurich and Nitin Sawant, Sr VP, Trivitron Healthcare announced the launch of NeoMass AAAC Kit patented by Trivitron in India and shared insights about newborn screening, its causes, global and Indian scenario, importance, facts and figures etc.

World’s First MRIdian Center Celebrates Two Years of MRI-Guided Radiation Treatments

January 11, 2016

ViewRay, Inc. (OTCQB: VRAY) announced today the two-year anniversary of treating patients with MRI-guided radiation therapy at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Mo.

An international leader in cancer treatment and research, Siteman Cancer Center has a rich history of adopting and helping to develop new technology with a focus on improving patient care and outcomes. In January 2014, Siteman Cancer Center began treating patients using the world’s first and only MRI-guided radiation therapy system – called MRIdian – that enables tumors to be visualized during treatment.

Ivenix Appoints MedTech Industry Veteran Stuart A. Randle as Chief Executive Officer

January 7, 2016

AMESBURY, Mass.–(BUSINESS WIRE)– Ivenix, Inc., a medical technology company developing a next-generation infusion management platform, today announced the appointment of seasoned medtech industry leader Stuart A. Randle to chief executive officer.

“We are delighted to welcome Stu with his extensive global commercialization experience to the Ivenix team,” stated Ketan Patel, M.D., chairman of the Ivenix board, and partner at F-Prime Capital Partners (the venture capital funds of FMR LLC, the parent company of Fidelity Investments). “The Ivenix Infusion Management System combines state-of-the-art information technology with simplicity and safety. In a cost-effective and clinically meaningful way, Ivenix is transforming the infusion system from being “smart” to being truly intelligent. Stu brings critical operational and commercial leadership experience at this important juncture in the company’s evolution from a development-stage to a pre-commercial stage company this year.”

ViewRay® to Present at the LD Micro “Main Event” Microcap Conference

November 24, 2015

ViewRay, Inc. (OTCQB:VRAY) announced that the Company will present at the 8th Annual LD Micro “Main Event” Microcap Conference in Los Angeles, CA.

The Company will be available for 1×1 meetings at the conference. Please contactviewray@theruthgroup.com for more information. The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 210 companies. An audio webcast of the Company’s presentation will be available online at www.viewray.com. A replay of the presentation will be available for 90 days.

ViewRay, Inc. of Cleveland, Ohio, is a medical device company that develops advanced radiation therapy technology for the treatment of cancer. The MRIdian® system provides continuous soft-tissue imaging during treatment, using MRI-guided radiation therapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient’s anatomy.

ViewRay to Present at the Stifel 2015 Healthcare Conference

November 12, 2015

ViewRay, Inc. (OTCQB: VRAY) announced today that Chris Raanes, Chief Executive Officer, and David Chandler, Chief Financial Officer, will present at the Stifel 2015 Healthcare Conference on November 18, 2015. This conference includes a formal presentation and will allow institutional investors to meet with Mr. Raanes and Mr. Chandler.

…

ViewRay’s MRI-Guided Radiation Therapy System Receives Korean Regulatory Marketing Approval

October 20, 2015

ViewRay, Inc., a medical device company, has received regulatory approval from the Ministry of Food and Drug Safety (MFDS) – formerly known as the Korean Food and Drug Administration (KFDA) – to sell its ViewRay system in Korea.

On October 13, 2015, the first patient treatments commenced less than four weeks after the system completed installation at Seoul National University Hospital (SNUH), a leading healthcare facility in Korea.

The first treatment at SNUH was for a patient with a single liver metastasis. Hong-Gyun Wu, M.D., Ph.D., professor and department chairman of SNUH chose the ViewRay system to treat the patient with stereotactic body radiation therapy (SBRT), because the system offers the accuracy needed, through real-time MRI imaging during treatment, to deliver the required high doses to the target and minimise damage to the surrounding healthy tissue.

Blog

Category: Medtech